세계의 중추신경계 바이오마커 시장 규모는 2025년 60억 4,000만 달러로 추정되며, 예측 기간 중(2025-2030년) CAGR 7.67%로 확대되어, 2030년에는 87억 4,000만 달러에 달할 것으로 예측됩니다.
세계의 COVID-19 증례는 CNS 바이오마커 시장에 큰 영향을 주었습니다. 2021년 1월에 발표된 연구 "뇌척수액의 중추신경계 손상에 대한 바이오마커는 COVID-19에서 상승하고 신경 증상 및 질병의 중증도와 관련이 있습니다.'에 따르면, 다양한 연구에서 COVID-19로 인한 입원 환자에서 신경 증상이 자주 보고되는 것으로 나타났습니다. 따라서 연구자들은 COVID-19의 신경학적 증상을 가진 환자의 뇌척수액(CSF), 중추 신경계(CNS) 부상 및 기타 병리학의 바이오 마커에 대한 신경학적 증상 상태와 질병의 중증도와의 연관성을 조사했습니다.
바이오마커는 생물학적 상태, 질환의 존재, 치료의 효과를 측정하기 위해 사용되었습니다. 단백질체학 연구는 중추 신경계의 진단과 치료 양쪽에서 관련 단백질 바이오마커의 발견에 큰 가능성을 갖고 있습니다.
또한 다양한 병태에서 바이오마커 개발을 위한 파이프라인 연구도 증가하고 있으며, 중추신경계 바이오마커 시장의 성장을 뒷받침할 것으로 기대되고 있습니다. 이오마커에 따르면, 특정 진단, 예후, 예측 바이오마커가 검출되어 이들은 계속 출현하고 있습니다.
따라서 첨단 영상 시스템은 사망률을 낮추면서 다양한 질병의 조기 진단에 도움이 됩니다. 진화에 반영됩니다. 중추 신경계(CNS)의 복잡성을 고려할 때, 바이오마커는 일부 신경 퇴행성 질환의 조기 발견, 진단 강화 및 나아가 더 나은 치료에 중요한 역할을 할 것으로 기대됩니다.
그러나 중추신경계 바이오마커 검사 및 진단 비용이 높고, 규제 및 상환 제도와 관련된 문제가 있는 것이 시장 성장을 저해하는 요인이 되고 있습니다.
정밀의료(맞춤형 의료)는 다양한 질병에 대처하기 위한 가장 유망한 접근법 중 하나임을 알고 있습니다.
COVID-19의 대유행은 맞춤형 의료 분야에 영향을 주었습니다. San Antonio Partnership for Precision Therapeutics(SAPPT)은 또한 정밀의료 원칙을 사용하여 COVID-19의 치료를 가속화하는 세 가지 프로젝트에 대한 자금 제공을 발표했습니다.
신경 퇴행성 질환에서의 바이오마커 조사는 맞춤형 의료에서 급속히 진전하고 있는 분야입니다. 이러한 마커의 역할은 진단뿐만 아니라, 예후의 가능성이나 새로운 치료법의 개발에 있어서의 역할도 담당하고 있습니다.
Precision Medicine의 진화는 바이오 의약품 업계에 큰 영향을 미치고 있으며, 바이오 의약품 회사에서 진단 약사에 이르기까지 연구 개발에서 상업 운영까지 여러 기능을 가진 여러 기업이 변화를 목격하게 됩니다.
만성질환 부담 증가, 단백질체학, 유전체학, 이미징 시스템 개발 진전, 맞춤형 의료 및 치료 채용 증가 등이 미국 중추신경계(CNS) 바이오마커 시장을 견인할 것으로 예상됩니다.
COVID-19의 입원 환자에서는 신경증상 증가가 빈번하게 보고되고, 중추신경계(CNS) 상해의 바이오마커는 혈장에서 증가하는 것으로 보고되고 있지만, 뇌척수액(CSF)에서는 광범위하게 연구되지 않았습니다. 따라서 COVID-19 증례 증가와 함께 혈청 바이오 마커를 사용하여 COVID-19 환자의 중추 신경계(CNS) 장애의 증거가 증가하고 있습니다.
2020년 GLOBOCAN의 추계에 따르면, 미국에서는 새롭게 암으로 진단된 환자는 228만 1,658명, 암에 의한 사망자는 61만 2,390명으로 추정되고 있습니다. 이를 위해 확실한 바이오마커의 발견과 검증을 촉진하는 접근법에 초점을 맞추었습니다.
분자 바이오마커는 중추신경계 질환의 진단, 예후 예측, 치료 효과 및 안전성 평가 등 다양한 목적으로 사용되고 있습니다.
2019년 MC10 Inc.는 중추신경계 질환의 신규 디지털 바이오마커 개발을 위한 로체스터 대학과의 공동 연구를 발표했습니다.
중추신경계 바이오마커 시장의 세계 기업으로는 Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd., Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciess, Merck Inc. 등을 들 수 있습니다. 각사는 전략적으로 연구개발에 투자하여 혁신적이고 기술적인 진보를 이루는 동시에 국내 기업과의 제휴에 주력하여 사업 확대를 도모하고 있습니다.
The Global Central Nervous System Biomarkers Market size is estimated at USD 6.04 billion in 2025, and is expected to reach USD 8.74 billion by 2030, at a CAGR of 7.67% during the forecast period (2025-2030).
COVID-19 cases worldwide had a profound impact on the CNS biomarkers market. Based on the study "Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity," published in January 2021, various studies found frequent reporting of neurological symptoms in patients hospitalized due to COVID-19. Thus, the researchers examined cerebrospinal fluid (CSF) from patients with neurological manifestations of COVID-19 for biomarkers of the central nervous system (CNS) injury and other pathology in relation to neurological symptoms and disease severity. Therefore, future studies in larger samples are needed to explore and understand the genesis of neurological injury in COVID-19 patients.
A biomarker is used to measure the biological state, presence of diseases, and effects of treatments. The advancements in the fields of genomics and proteomics during the past decade have improved awareness regarding genetic regulatory pathways related to (central nervous system) CNS biomarkers. The proteomics technologies have advanced in various areas of drug discovery and development through a comparative assessment of normal and diseased tissues. Proteomics research has great potential in the discovery of relevant protein biomarkers in both diagnostics and therapies for the central nervous system. It plays a crucial role in earlier disease diagnosis, prognosis, and monitoring of the development of central nervous disease.
There is also an increasing number of pipeline studies for the development of biomarkers in various disease conditions, which is expected to boost the central nervous system biomarkers market growth. According to the study "Biomarkers in tumors of the central nervous system" published in 2019, specific diagnostic, prognostic, and predictive biomarkers were detected, and they continue to emerge. Hence, the knowledge of specific biomarkers is of great importance for individualized treatment and follow-up.
Therefore, advanced imaging systems are aiding the early diagnosis of various diseases while reducing the mortality rate. The development in related technologies, such as genomics, proteomics, and imaging system, is reflected in the evolution of newer biomarkers. Considering the complexity of the central nervous system (CNS), biomarkers are now expected to play a significant role in the identification of several neurodegenerative diseases at an early stage, provide enhanced diagnosis, and eventually better treatment.
However, the high cost of CNS biomarker testing and diagnostics and certain issues related to regulatory and reimbursement systems are found to be the hindering factors impacting the growth of the market.
Precision medicine, or personalized medicine, is found to be one of the most promising approaches to tackling various diseases. The major factors that are contributing to the growth of the market are the rising number of brain and other nervous system cancers. It has its rising application as a diagnostic tool, which helps in recognizing the precise biological markers. There is an increasing number of companies that are found focusing on developing breakthrough products for the treatment of neurological diseases.
The COVID-19 pandemic impacted the personalized medicine segment. Precision medicine (PM) aims to tailor treatment and interventions to unique individual or population-level traits. Therefore, personalized medicine is relevant for addressing COVID-19 illness. The San Antonio Partnership for Precision Therapeutics (SAPPT) also announced the funding of three projects that would accelerate treatments for COVID-19 using precision medicine principles.
Biomarker research in neurodegenerative disease is a rapidly advancing area in personalized medicine. The role of these markers is not only diagnostic, but they also have prognostic potential or role in the development of new treatments. Therefore, a large number of molecules have been evaluated and associated with different neurodegenerative disorders. Alzheimer's disease and Parkinson's disease are found to be the two most common neurodegenerative disorders.
This evolution within precision medicine has profoundly impacted the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change. Therefore, all these factors have helped in boosting the overall market.
The growing burden of chronic diseases, rise in the development of proteomics, genomics, and imaging systems, and increasing adoption of personalized medicines and therapy are expected to drive the central nervous system (CNS) biomarkers market in the United States.
The increasing neurological symptoms have been frequently reported in hospitalized patients with COVID-19, and biomarkers of central nervous system (CNS) injury are reported to be increased in plasma but not extensively studied in cerebrospinal fluid (CSF). Therefore with the rising COVID-19 cases, there is increasing evidence of central nervous system (CNS) damage in COVID-19 patients by using serological biomarkers.
According to the estimates of the GLOBOCAN in 2020, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the United States. The National Institute of Neurological Disorders and Stroke is mainly focusing on approaches that could facilitate the discovery and validation of robust biomarkers, primarily for better diagnosis and treatment of certain conditions. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.
The molecular biomarkers are used for various purposes, including CNS disease diagnosis, prognosis, prediction, and assessment of treatment response and safety. Almost every pharmaceutical company is formulating a molecular biomarker program, either alone or through partnerships. More molecular biomarkers are expected to be identified and validated in drug development.
In 2019, MC10 Inc. announced the collaboration with the University of Rochester for the development of novel digital biomarkers for central nervous system diseases. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.
The global players in the central nervous system biomarkers market include Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd, Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, Merck KGaA, and Thermo Fisher Scientific Inc. The players strategically invest in the research and development for innovative and technological advancements and focus on partnerships with domestic players to expand their outreach.